We report a case of M. chelonae-associated parotitis in a 35-year-old woman. She presented with complaints of painful swelling and redness of the angle of her left jaw that started 1 month prior to admission. She reported that it started as a small 1-cm swelling in the middle aspect of her left jaw that gradually progressed to the angle. She was started on oral clindamycin and levaquin. There was no clinical improvement after a week of therapy. She started experiencing a pulsating pain that was aggravated by eating. A week prior to admission, she noticed progression of the redness and swelling to the left earlobe. She denied having any fever, chills, fatigue, weight loss or hearing impairment. She had a past medical history of neonatal portal vein thrombosis, splenectomy in 1992; and esophagogastric varices diagnosed by endoscopy two years ago. She was originally from Spain and had immigrated to the United States 15 years ago. She gave no personal or family history of tuberculosis. Her father had thyroid cancer. She did not have any history of recent travel. Physical examination [Figure 1] revealed a mobile and tender mass measuring approximately 3 cm and occupying the superficial lobe of the left parotid gland. There were overlying erythematous skin changes suggestive of parotitis. Facial nerve function was normal. Other physical findings were also normal, and there was no palpable cervical lymphadenopathy. The complete blood count, erythrocyte sedimentation rate, results of other biochemical/ autoimmune investigations and chest X-ray were normal. The result of the Human Immunodeficiency Virus (HIV) antibody test was negative. She had a tuberculin test done, which was measured at 4 mm (negative). CT scan  [Figure 2] showed diffuse enhancement of the left parotid gland with an enlarged soft tissue mass lesion, measuring 3 x 4 cm in size, with a cystic component. A CT-guided fine-needle aspiration was performed, and the smear came back positive for acid-fast bacilli (AFB) [Figure 3]. The working diagnosis at that time was M. tuberculosis-related parotitis, and our patient was empirically treated with oral antitubercular meds (rifampin 300 mg, isoniazid 150 mg, ethambutol 400 mg and pyrazinamide 1000 mg once a day). Ten days later, the cultures grew AFB; and utilizing the genotype TB system (Hain, Nehren), the AFB was identified as Mycobacterium chelonae. Drug susceptibility report showed the organism to be resistant to imipenem, amikacin, ciprofloxacin, cefoxitin and linezolid; and sensitive to clarithromycin. The antitubercular regimen was discontinued, and she was started on oral clarithromycin 500 mg twice a day, with some evident resolution of symptoms, size and inflammation after 3 months of therapy. The management plan wasto continue this antibiotic regimen for at least six months and to regularly follow up with her during the duration of therapy.